CD274 and neoplasm: When combined with anti-PD-L1 antibodies, this strategy suppressed both primary and distant tumors in 4T1 and CT26 models and prevented lung metastasis, providing a compelling proof-of-concept for integrating immunotherapy with non-invasive tumor treatments [126].